Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
What is the ticker symbol for Reviva Pharmaceuticals Holdings? What does RVPH stand for in stocks?
RVPH is the stock ticker symbol of Reviva Pharmaceuticals Holdings. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Reviva Pharmaceuticals Holdings (RVPH)?
As of Wed Nov 20 2024, market cap of Reviva Pharmaceuticals Holdings is 40.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of RVPH stock?
You can check RVPH's fair value in chart for subscribers.
Is Reviva Pharmaceuticals Holdings a good stock to buy?
The fair value guage provides a quick view whether RVPH is over valued or under valued. Whether Reviva Pharmaceuticals Holdings is cheap or expensive depends on the assumptions which impact Reviva Pharmaceuticals Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVPH.